Chapters authored
Chronic Obstructive Pulmonary Disease (COPD): Clinical and Immunological Effects of Mono-Vaccination Against Influenza Using an Immunoadjuvant Vaccine of a New Class Versus Combined Administration S. pneumoniae, H. influenzae, and Influenza Vaccines
In Russian Federation, 27,300,000–41,200,000 acute upper and lower respiratory infections are reported annually. Patients with chronic obstructive pulmonary disease (COPD) are at higher risk of severe course, complications, and lethal outcomes of influenza. About 30% of COPD exacerbations are due to viral infections, and influenza A and B viruses are among the most common causes. The aim of our study was to assess exacerbation rate, number of courses of antibiotic chemotherapy, pulmonary function, and immunological effects of mono-vaccination with a new immunoadjuvant influenza vaccine vs. combined vaccination against pneumococcal infection, Hemophilus type b infection, and influenza in COPD patients. Both complex vaccination against Streptococcus pneumoniae, Haemophilus influenzae type b, and influenza and mono-vaccination with a new immunoadjuvant influenza vaccine led to statistically significant reduction in the number of COPD exacerbations and of antibiotic chemotherapy courses. Based on the obtained results, widespread implementation of mono-vaccination against influenza with a new immunoadjuvant influenza vaccine, as well as complex vaccination against bacterial respiratory infections and influenza can be recommended for COPD patients, as vaccination is beneficial for their functional status, that is, improves forced expiratory volume in 1 s (FEV1) and 6-minute walk test results. In our study, we evaluated immunogenicity of the new influenza immunoadjuvant vaccine administered as mono-vaccine to COPD patients in accordance with Committee for Proprietary Medicinal Products (CPMP) requirements.
Part of the book: Steps Forwards in Diagnosing and Controlling Influenza